Page last updated: 2024-12-10

mivacurium

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Mivacurium: An isoquinoline derivative that is used as a short-acting non-depolarizing agent. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5281042
CHEMBL ID1182833
CHEBI ID6958
SCHEMBL ID10014476
SCHEMBL ID10666872
MeSH IDM0141623

Synonyms (28)

Synonym
mivacron
mivacurium
C07550
DB01226
NCGC00167469-01
bwb109ou
bw-b109ou
NCGC00183094-01
isoquinolinium, 2,2'-((1,8-dioxo-4-octene-1,8-diyl)bis(oxy-3,1-propanediyl))bis(1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-((3,4,5-trimethoxyphenyl)methyl)-, (1r-(1r*(e(1'r*))))-
133814-19-4
unii-77d66s9q93
bis[3-[(1r)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1h-isoquinolin-2-ium-2-yl]propyl] (e)-oct-4-enedioate
mivacurium cation
bw b109ou
chebi:6958 ,
mivacurium ion
CHEMBL1182833
tox21_112909
dtxsid6048333 ,
cas-133814-19-4
dtxcid7028308
77d66s9q93 ,
gtpl7243
(1r)-2-(3-{[(4e)-8-{3-[(1r)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-2-ium-2-yl]propoxy}-8-oxooct-4-enoyl]oxy}propyl)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-2-
SCHEMBL10014476
SCHEMBL10666872
Q413877
NCGC00167469-02

Research Excerpts

Overview

Mivacurium is a short-acting non-depolarizing muscle relaxant, which is hydrolyzed by butyrylcholinesterase. It is an effective drug for use in burns, irrespective of time after, or magnitude of burn injury. Mivayurium has been implicated in a number of homicides.

ExcerptReferenceRelevance
"Mivacurium is a non-depolarizing muscle relaxant and widely used as a short-acting anesthetic. "( Mivacurium induce mast cell activation and pseudo-allergic reactions via MAS-related G protein coupled receptor-X2.
An, H; Cao, J; Che, D; Ding, Y; Gao, Z; Hou, Y; Liu, R; Wang, J; Zhang, T; Zhang, Y, 2018
)
3.37
"Mivacurium is a short-acting non-depolarizing muscle relaxant, which is hydrolyzed by butyrylcholinesterase. "( Reversal of mivacurium-induced neuromuscular blockade with a cholinesterase inhibitor: A systematic review.
Brinch, JHW; Gätke, MR; Madsen, MV; Söderström, CM, 2019
)
2.34
"Mivacurium is an effective drug for use in burns, irrespective of time after, or magnitude of burn injury."( Pharmacodynamics of mivacurium chloride in 13- to 18-yr-old adolescents with thermal injury.
Chang, Y; Goudsouzian, NG; Martyn, JA; Patel, SS, 2002
)
1.36
"Mivacurium is a mixture of three isomers, two of which are rapidly broken down in vivo by plasma cholinesterases. "( Stereoselective in vitro degradation pattern of mivacurium in human plasma.
Donati, F; Laurin, J; Varin, F, 2002
)
2.01
"Mivacurium is a short-acting neuromuscular blocking drug, ideal for short surgical procedures. "( Prolonged neuromuscular blockade as a result of malnutrition-induced pseudocholinesterase deficiency.
Leonard, IE; Niazi, A; O'Kelly, B, 2004
)
1.77
"Mivacurium is a muscle relaxant that is used in hospitals and has been implicated in a number of homicides. "( The identification of mivacurium and metabolites in biological samples.
Jufer, RA; LeBeau, MA; Miller, ML; Montgomery, MA, 2005
)
2.09
"Mivacurium chloride is a bis-benzylisoquinolinium nondepolarizing neuromuscular blocking agent, hydrolyzed by butyrylcholinesterase (PCHE). "( Enzymatic antagonism of mivacurium-induced neuromuscular blockade by human plasma cholinesterase.
Altamimi, W; Ammar, A; Daoud, W; el-Gammal, M; Naguib, M; Selim, M; Sohaibani, MO; Turkistani, A, 1995
)
2.04
"Mivacurium is a potent nondepolarising neuromuscular blocking agent which is structurally related to the benzylisoquinolinium compound, atracurium. "( Mivacurium. A review of its pharmacology and therapeutic potential in general anaesthesia.
Frampton, JE; McTavish, D, 1993
)
3.17
"Mivacurium is a relatively new short-acting nondepolarizing neuromuscular blocker. "( Prolonged neuromuscular block associated with mivacurium.
Fox, MH; Hunt, PC, 1995
)
1.99
"Mivacurium is a non-depolarizing muscle relaxant with a relatively rapid onset and a short duration of action, and to date it has been proved safe in MH-susceptible patients."( Neuroleptic malignant syndrome and mivacurium: a safe alternative to succinylcholine?
Brull, SJ; Kelly, D, 1994
)
1.29
"Mivacurium appears to be an ideal agent for neuromuscular blockade in myasthenia gravis as long as careful neuromuscular blockade is performed."( Isoflurane and mivacurium chloride neuromuscular blockade in patients with myasthenia gravis.
Mangar, D; Stillwell, R; Turnage, WS, 1993
)
1.36
"Mivacurium is a short-acting benzylisoquinolinium that is rapidly hydrolysed by plasma cholinesterases."( Pharmacokinetics and pharmacodynamics of the benzylisoquinolinium muscle relaxants.
Hull, CJ, 1995
)
1.01
"Mivacurium is a benzylisoquinolinium diester. "( The clinical and basic pharmacology of mivacurium: a short-acting nondepolarizing benzylisoquinolinium diester neuromuscular blocking drug.
Belmont, MR; Lien, CA; Rubin, L; Savarese, JJ, 1995
)
2
"Mivacurium is a new nondepolarizing muscle relaxant of the benzylisoquinoline type. "( Mivacurium chloride--a comparative profile.
Buzello, W; Diffenbach, C; Mellinghoff, H, 1995
)
3.18
"Mivacurium is a new non-depolarizing muscle relaxant consisting of three stereoisomers. "( Edrophonium requirements for reversal of deep neuromuscular block following infusion of mivacurium.
Bragg, P; Bryson, G; Curran, M; Hull, K; Kitts, JB; Lindsay, P; Martineau, RJ; Miller, DR; Watson, JB, 1995
)
1.96
"Mivacurium is a new neuromuscular blocking agent with a short acting time of about 30 min, due to a fast hydrolysis by pseudocholinesterases. "( [Prolonged neuromuscular block after administration of mivacurium caused by plasma psueudocholinesterase deficiency].
Kaiser, E; Petit, D; Quinot, JF; Sallaberry, M; Suppini, A, 1995
)
1.98
"Mivacurium is a new non-depolarising muscle relaxant with a relatively rapid onset and short duration of action. "( [Effect of halothane, enflurane and isoflurane on the pharmacodynamics of mivacurium in children].
Kuhn, I; Leuwer, M; Neidhart, G; Pabelick, C; Vettermann, J, 1996
)
1.97
"Mivacurium is a short-acting nondepolarising muscle relaxant of the benzylisoquinoline type undergoing rapid breakdown by plasma cholinesterase. "( [New muscle relaxants].
Buzello, W; Diefenbach, C, 1996
)
1.74
"Mivacurium is a potent, short-acting, nondepolarizing relaxant of the benzylisoquinoline series. "( [Mivacurium in pediatric anesthesia].
Benad, G; Hofmockel, VR; Pohl, B, 1996
)
2.65
"Mivacurium is a short-acting, nondepolarising muscle relaxant of the benzylisoquinoline type that undergoes rapid breakdown by plasma cholinesterase. "( [The clinical pharmacology of mivacurium].
Diefenbach, C; Mellinghoff, H, 1997
)
2.03
"Mivacurium is a short-acting non-deplolarizing neuromuscular blocking agent. "( Mivacurium in an obese patient with myotonic dystrophy--a case report.
Antakly, MC; el Hage, C; Richa, F; Yazigi, A, 1997
)
3.18
"Mivacurium is a short-acting nondepolarizing muscle relaxant (NDPMR) with a benzyl-isoquinoline structure and rapid, spontaneous reversal. "( [Mivacurium].
Carrascosa, F; Ortiz, JR, 1997
)
2.65
"Mivacurium is a racemate of 3 stereoisomeres of which the trans-trans- and the cis-trans-compound account for 95% of the neuromuscular blocking effect."( [The clinical pharmacology of new benzylisoquinoline-diester compounds, with special consideration of cisatracurium and mivacurium].
Belmont, MR; Lien, CA; Savarese, JJ; Wastila, WB, 1997
)
1.23
"Mivacurium is a short acting non-depolarising neuromuscular blocking agent. "( [Prolonged neuromuscular blockade with mivacurium in a newborn].
Doucet, O; Jonville-Bera, AP; Laffon, M; Martin, L; Mercier, C, 1998
)
2.01
"Mivacurium is a mixture of 3 stereoisomers."( Clinical pharmacokinetics of the newer neuromuscular blocking drugs.
Atherton, DP; Hunter, JM, 1999
)
1.02
"Mivacurium is a muscle relaxant, degraded by plasma cholinesterase, whose enzyme activity is decreased in burns."( Neuromuscular effects of mivacurium in 2- to 12-yr-old children with burn injury.
Chang, Y; Goudsouzian, NG; Martyn, JA; Patel, SS; Schwartz, AE; Szyfelbein, SK, 2000
)
1.33
"Mivacurium is a short-acting, nondepolarizing neuromuscular blocking agent hydrolyzed by plasma cholinesterase. "( Prolonged neuromuscular block with mivacurium in a patient with cholinesterase deficiency.
Chen, C; Huang, CS; Lee, YH; Liou, SC; Wong, TK, 2000
)
2.03
"Mivacurium is a benzylisoquinolone, choline-like, non-depolarizing muscle relaxant. "( Prolonged paralysis following mivacurium administration.
Chung, DY; Hardman, J, 2002
)
2.05
"Mivacurium is a muscle relaxant with a short duration of action."( Newer neuromuscular blocking drugs. An overview of their clinical pharmacology and therapeutic use.
Mirakhur, RK, 1992
)
1
"Mivacurium chloride is a new, short-acting nondepolarizing neuromuscular blocking agent presently undergoing clinical evaluation. "( Comparison of mivacurium and suxamethonium administered by bolus and infusion.
Brandom, BW; Cook, DR; Powers, DM; Weakly, JN; Weber, S; Woelfel, SK, 1989
)
2.08
"Mivacurium is a new short-acting competitive neuromuscular blocking agent. "( Continuous infusion of mivacurium in children.
Alifimoff, JK; Goudsouzian, NG, 1989
)
2.03

Effects

Mivacurium has a short duration of action due to its rapid elimination by plasma cholinesterase.

Mivacurium chloride has been assessed in respect of intubating conditions and neuromuscular effects. It has a short duration of action because it is rapidly hydrolysed by plasma cholinesterase.

ExcerptReferenceRelevance
"Mivacurium has a short duration of action due to its rapid elimination by plasma cholinesterase."( Mivacurium. A review of its pharmacology and therapeutic potential in general anaesthesia.
Frampton, JE; McTavish, D, 1993
)
2.45
"Mivacurium has a short duration of action because it is rapidly hydrolysed by plasma cholinesterase. "( [Neostigmine and edrophonium. Antagonism of profound and shallow mivacurium blockade].
Bartunek, A; Foldes, FF; Gilly, H; Huemer, G; Lackner, FX; Schramm, W; Yildiz, S, 1997
)
1.98
"Mivacurium has a short duration of action due to its rapid elimination by plasma cholinesterase."( Mivacurium. A review of its pharmacology and therapeutic potential in general anaesthesia.
Frampton, JE; McTavish, D, 1993
)
2.45
"Mivacurium chloride has been assessed in respect of intubating conditions and neuromuscular effects. "( Neuromuscular effects and intubating conditions following mivacurium: a comparison with suxamethonium.
Clarke, RS; Fee, JP; Maddineni, VR; McCoy, EP; Mirakhur, RK, 1993
)
1.97
"Mivacurium has been little studied in infants and children without a volatile anaesthetic agent. "( Mivacurium chloride in infants and children.
Meretoja, OA; Taivainen, T, 1995
)
3.18
"Mivacurium has a short duration of action because it is rapidly hydrolysed by plasma cholinesterase. "( [Neostigmine and edrophonium. Antagonism of profound and shallow mivacurium blockade].
Bartunek, A; Foldes, FF; Gilly, H; Huemer, G; Lackner, FX; Schramm, W; Yildiz, S, 1997
)
1.98
"Mivacurium has also been licensed for use in the US."( Newer neuromuscular blocking drugs. An overview of their clinical pharmacology and therapeutic use.
Mirakhur, RK, 1992
)
1

Actions

Mivacurium is unique because it is metabolized by plasma cholinesterase which produces a rapid recovery although slower than succinylcholine. The increase in Raw (28.7%) in group C was significantly higher than that in group AH (6.6%)

ExcerptReferenceRelevance
"Mivacurium is unique because it is metabolized by plasma cholinesterase which produces a rapid recovery although slower than succinylcholine."( Newer neuromuscular blocking agents.
Bevan, DR, 1994
)
1.01
"The mivacurium-induced increase in Raw (28.7 +/- 2.3%; mean +/- SD) in group C was significantly higher than that in group AH (6.6 +/- 3.4%), whereas the responses in G were not inhibited significantly (23.9 +/- 6.9% vs."( Role of endogenous histamine in altered lung mechanics in rabbits.
Babik, B; Chalier, M; Habre, W; Peták, F, 2002
)
0.8

Treatment

Mivacurium had a marked antagonistic effect on the development of subsequent depolarizing block produced by suxamethonium.

ExcerptReferenceRelevance
"Mivacurium pretreatment did not produce relevant clinical changes."( [Interaction between mivacurium and succinylcholine from a different point of view].
Steinberg, D, 2006
)
1.37
"Pretreatment with mivacurium had a marked antagonistic effect on the development of subsequent depolarizing block produced by suxamethonium."( Dose-response studies of the interaction between mivacurium and suxamethonium.
Abdulatif, M; al-Ghamdi, A; Naguib, M; Selim, M, 1995
)
0.87

Toxicity

ExcerptReferenceRelevance
" Mivacurium is a non-depolarizing muscle relaxant with a relatively rapid onset and a short duration of action, and to date it has been proved safe in MH-susceptible patients."( Neuroleptic malignant syndrome and mivacurium: a safe alternative to succinylcholine?
Brull, SJ; Kelly, D, 1994
)
1.48

Pharmacokinetics

The transtrans and cis-trans isomers of mivacurium have a long half-life and slow clearance in healthy dogs anesthetized with halothane.

ExcerptReferenceRelevance
" The current study was undertaken to determine the pharmacokinetic profile of the individual stereoisomers of mivacurium, to evaluate the dose-proportionality of the more potent trans-trans and cis-trans isomers, and to evaluate the pharmacodynamics of mivacurium in healthy adult patients receiving a consecutive two-step infusion of mivacurium."( The pharmacokinetics and pharmacodynamics of the stereoisomers of mivacurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia.
Belmont, MR; Embree, PB; Lien, CA; Savarese, JJ; Schmith, VD; Wargin, WA, 1994
)
0.74
" Pharmacokinetic parameters were determined using noncompartmental analysis."( The pharmacokinetics and pharmacodynamics of the stereoisomers of mivacurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia.
Belmont, MR; Embree, PB; Lien, CA; Savarese, JJ; Schmith, VD; Wargin, WA, 1994
)
0.53
" Atracurium can be used as a pharmacokinetic benchmark; it has at least two distinct metabolic pathways, of which Hofmann elimination and ester hydrolysis are the most significant."( Pharmacokinetics and pharmacodynamics of the benzylisoquinolinium muscle relaxants.
Hull, CJ, 1995
)
0.29
" This pharmacodynamic profile makes mivacurium preferable for intermittent on-demand neuromuscular blockade in the severely burned patient."( Pharmacodynamics of mivacurium in severely burned patients.
Bayer, GS; Maitz, PK; Neiger, FX; Schultz, AM; Werba, AE; Wolrab, C, 1996
)
0.89
" Although the extent of the mivacurium arterial-venous gradient is not known, the sampling site is likely to influence mivacurium pharmacokinetic parameters because the drug is rapidly metabolized as it traverses the circulation."( Pharmacokinetics of mivacurium isomers and their metabolites in healthy volunteers after intravenous bolus administration.
Donati, F; Lacroix, M; Varin, F, 1997
)
0.91
" Plasma concentrations of mivacurium isomers and their metabolites were determined by two stereoselective high-performance liquid chromatographic methods coupled with fluorometric detection and noncompartmental pharmacokinetic parameters."( Pharmacokinetics of mivacurium isomers and their metabolites in healthy volunteers after intravenous bolus administration.
Donati, F; Lacroix, M; Varin, F, 1997
)
0.92
" Here, they determined whether there are differences between children and adults in mivacurium's pharmacokinetic and pharmacodynamic properties."( The pharmacokinetics and steady state pharmacodynamics of mivacurium in children.
Brown, R; Fisher, DM; Lau, M; Luks, AM; Markakis, DA; Sharma, ML, 1998
)
0.77
" Pipecuronium resembles pancuronium in its pharmacokinetic and neuromuscular blocking profile, but is devoid of cardiovascular effects."( Clinical pharmacokinetics of the newer neuromuscular blocking drugs.
Atherton, DP; Hunter, JM, 1999
)
0.3
"To determine pharmacokinetic variables of mivacurium chloride after IV administration in dogs."( Pharmacokinetic variables of mivacurium chloride after intravenous administration in dogs.
Cook, DR; Looney, AL; Moon, PF; Schwark, WS; Smith, LJ, 1999
)
0.86
"024 L/kg, median half-life was 34."( Pharmacokinetic variables of mivacurium chloride after intravenous administration in dogs.
Cook, DR; Looney, AL; Moon, PF; Schwark, WS; Smith, LJ, 1999
)
0.59
"The transtrans and cis-trans isomers of mivacurium have a long half-life and slow clearance in healthy dogs anesthetized with halothane."( Pharmacokinetic variables of mivacurium chloride after intravenous administration in dogs.
Cook, DR; Looney, AL; Moon, PF; Schwark, WS; Smith, LJ, 1999
)
0.86
"To determine pharmacodynamic effects and safety of mivacurium in paediatric patients."( [Pharmacodynamics and safety of mivacurium in infants and children under halothane-nitrous oxide anesthesia].
Ecoffey, C; Goujard, E; Meistelman, C; Orliaguet, G; Plaud, B, 1999
)
0.84
"For anesthetic drugs undergoing nonorgan-based elimination, there is a definite trend towards using pharmacokinetic (PK) models in which elimination can occur from both central (k10) and peripheral compartments (k20)."( Assuming peripheral elimination: its impact on the estimation of pharmacokinetic parameters of muscle relaxants.
Donati, F; Laurin, J; Nekka, F; Varin, F, 1999
)
0.3
" The pharmacokinetic data were too sparse to allow analysis of the two age groups separately (8 and 8 patients), hence the data were pooled."( The pharmacodynamics and pharmacokinetics of mivacurium in children.
Berg, H; Gätke, MR; Rasmussen, SN; Viby-Mogensen, J; ØStergaard, D, 2002
)
0.57
" Thirty-two patients were randomly selected for the pharmacokinetic study."( Pharmacokinetics and pharmacodynamics of mivacurium in young adult and elderly patients.
Holm, H; Pedersen, NA; Skovgaard, LT; Viby-Mogensen, J; ØStergaard, D, 2002
)
0.58
" No statistically significant difference between the age groups in clearance and elimination half-life of the isomers was seen."( Pharmacokinetics and pharmacodynamics of mivacurium in young adult and elderly patients.
Holm, H; Pedersen, NA; Skovgaard, LT; Viby-Mogensen, J; ØStergaard, D, 2002
)
0.58
" In the current study we performed a pharmacokinetic analysis by measuring the plasma concentration of mivacurium when preceded by administration of a low dose of pancuronium."( Potentiation of mivacurium blockade by low dose of pancuronium: a pharmacokinetic study.
Bouleau, D; Combes, X; Duvaldestin, P; Farinotti, R; Feiss, P; Kirov, K; Menad, R; Motamed, C, 2003
)
0.88
" Twelve of the patients with an estimated duration of anaesthesia of more than 90 min were (randomly) selected for the pharmacokinetic part of the study."( Pharmacokinetics and pharmacodynamics of mivacurium in patients phenotypically heterozygous for the usual and atypical plasma cholinesterase variants (UA).
Gätke, MR; Pedersen, NA; Rasmussen, SN; Skovgaard, LT; Viby-Mogensen, J; Østergaard, D, 2003
)
0.58
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" We tested whether the decreased metabolism of mivacurium due to decreased PChE activity can overcome the pharmacodynamic resistance to non-depolarizing relaxants previously seen in major burns."( Neuromuscular pharmacodynamics of mivacurium in adults with major burns.
Han, TH; Martyn, JA, 2011
)
0.91

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Thirty patients received mivacurium and 20 patients received pancuronium to establish dose-response curves for these agents. Etomidate, due to its short half-life, seems not ideal for induction of a TIVA together with mivayurium in the dosage used.

ExcerptRelevanceReference
"The dose-response relationship and neuromuscular blockade after infusion or repeated injection of mivacurium were studied in 65 patients in nitrous oxide-narcotic anesthesia."( Mivacurium: dose-response relationship and administration by repeated injection or infusion.
Buzello, W; Diefenbach, C; Lynch, J; Mellinghoff, H, 1992
)
1.94
" These doses were based on the assumption that the slope of the dose-response curve during nitrous oxide-opioid anaesthesia would be approximately the same as the slope of the neuromuscular response from the first human studies with mivacurium."( Neuromuscular and cardiovascular effects of mivacurium chloride (BW B1090U) during nitrous oxide-fentanyl-thiopentone and nitrous oxide-halothane anaesthesia.
Abou-Donia, M; Choi, WW; From, RP; Pearson, KS; Sokoll, MD, 1990
)
0.72
" There was no significant difference between the slopes of the HAL and BAL inhalation anesthetic dose-response curves."( Neuromuscular and cardiovascular effects of mivacurium chloride (BW B109OU) during nitrous oxide-narcotic, nitrous oxide-halothane and nitrous oxide-isoflurane anesthesia in surgical patients.
Abou-Donia, M; Choi, WW; From, RP; Pearson, KS; Sokoll, MD, 1990
)
0.54
"The dose-response relationships of mivacurium chloride during N2O/fentanyl or N2O/enflurane anesthesia were compared in 70 patients intraoperatively."( The dose-response relationship of mivacurium chloride in humans during nitrous oxide-fentanyl or nitrous oxide-enflurane anesthesia.
Caldwell, JE; Fahey, MR; Heier, T; Kitts, JB; Lynam, DP; Miller, RD, 1989
)
0.83
"We determined the dose-response relationships of mivacurium (BW B1090U) in children (2-10 years) during nitrous oxide-halothane anesthesia (0."( Clinical pharmacology of mivacurium chloride (BW B1090U) in children during nitrous oxide-halothane and nitrous oxide-narcotic anesthesia.
Brandom, BW; Cook, DR; Dong, ML; Foster, VJ; Horn, MC; McNulty, BF; Sarner, JB; Woelfel, SK, 1989
)
0.83
"kg-1 to study the dose-response relationships, as well as the cardiovascular effects of mivacurium."( Neuromuscular and cardiovascular effects of mivacurium chloride in surgical patients receiving nitrous oxide-narcotic or nitrous oxide-isoflurane anaesthesia.
Abou-Donia, M; Choi, WW; Forbes, RB; Gergis, SD; Kirchner, J; Mehta, MP; Murray, DJ; Sokoll, MD, 1989
)
0.76
" Firstly we established dose-response curves for mivacurium and pancuronium."( Synergism between mivacurium and pancuronium in adults.
Erkola, O; Meretoja, OA; Rautoma, P, 1995
)
0.88
" The dose-response relationships for PCHE after mivacurium have not been studied."( Enzymatic antagonism of mivacurium-induced neuromuscular blockade by human plasma cholinesterase.
Altamimi, W; Ammar, A; Daoud, W; el-Gammal, M; Naguib, M; Selim, M; Sohaibani, MO; Turkistani, A, 1995
)
0.85
" Etomidate, due to its short half-life, seems not ideal for induction of a TIVA together with mivacurium in the dosage used."( [Intubation conditions and circulatory effects 90 seconds after a divided mivacurium dose with three different TIVA induction methods].
Geldner, GF; Hetz, W; Rügheimer, E; Schweiger, S, 1995
)
0.74
"We have compared the dose requirements and recovery characteristics of a continuous mivacurium infusion given by the anaesthetist to maintain 95-100% block at the hand muscles with that of a surgeon-controlled, on-demand dosing technique based on the direct assessment of abdominal muscle tone during elective Caesarean section."( Surgeon-controlled mivacurium administration during elective caesarean section.
Abdulatif, M; Taylouni, E, 1995
)
0.84
" Single dose-response curves were determined by probit analysis."( Dose-response studies of the interaction between mivacurium and suxamethonium.
Abdulatif, M; al-Ghamdi, A; Naguib, M; Selim, M, 1995
)
0.55
" The dose-response relationships of atracurium, mivacurium and their combination were studied in 96 ASA I or II patients during thiopentone-fentanyl-nitrous oxide-isoflurane (1."( Interactions between mivacurium and atracurium.
Abdulatif, M; al-Ghamdi, A; el-Sanbary, M; Magboul, MA; Naguib, M; Selim, M; Seraj, M, 1994
)
0.86
"In the first study, the dose-response relations of rocuronium, mivacurium, and their combination were studied in ASA physical status 1 or 2 patients during thiopental-fentanyl-N2O anesthesia."( Neuromuscular effects of rocuronium bromide and mivacurium chloride administered alone and in combination.
Naguib, M, 1994
)
0.78
"We determined the dose-response relationship of mivacurium in infants 2-6 and 7-11 mo of age during nitrous oxide-halothane anesthesia."( Clinical pharmacology of mivacurium in pediatric patients less than off years old during nitrous oxide-halothane anesthesia.
Brandom, BW; Cook, DR; McGowan, FX; Woelfel, SK, 1993
)
0.85
" This study was designed to evaluate the neuromuscular effects of mivacurium by dose-response analysis, and its cardiovascular effects in 90 infants 2-11 months of age anesthetized with 1% halothane and nitrous oxide:oxygen."( Pharmacodynamic and hemodynamic effects of mivacurium in infants anesthetized with halothane and nitrous oxide.
Denman, W; Foster, V; Goudsouzian, NG; Samara, B; Schwartz, A; Shorten, G, 1993
)
0.79
" The first four doses in each group were used to determine dose-response relationships."( Pharmacodynamic and hemodynamic effects of mivacurium in infants anesthetized with halothane and nitrous oxide.
Denman, W; Foster, V; Goudsouzian, NG; Samara, B; Schwartz, A; Shorten, G, 1993
)
0.55
"We have studied the dose-response relationships for neostigmine and edrophonium during antagonism of neuromuscular block induced by mivacurium chloride."( Dose-response relationships for edrophonium and neostigmine antagonism of mivacurium-induced neuromuscular block.
Abdulatif, M; al-Ghamdi, A; Hamo, I; Naguib, M; Nouheid, R, 1993
)
0.72
" Dose-response curves were constructed using a single-dose method for each mode of stimulation."( Potency estimation of mivacurium: comparison of two different modes of nerve stimulation.
Cooper, R; Maddineni, VR; McCoy, E; Mirakhur, RK, 1993
)
0.6
"The aim of our randomized controlled study was to compare the neuromuscular characteristics of mivacurium and atracurium by evaluating the intubation conditions, intubation times, onset times and the duration of action of these two muscle relaxants using two different dosing principles."( [Comparison of neuromuscular blockade by mivacurium and atracurium].
Benad, G; Hofmockel, R; Jantschulev, S, 1995
)
0.78
" No difference in intubation scores or number of intubation attempts among the three dosage groups were found."( Intubating conditions and neuromuscular effects of mivacurium during propofol-alfentanil anaesthesia.
Crul, JF; Ory, JP; Van Aken, H; Vandermeersch, E; Vertommen, JD, 1995
)
0.54
"During thiopentone-fentanyl-nitrous oxide anaesthesia and using a cumulative design, we studied the dose-response relationship of mivacurium in 8 patients: 7 patients phenotypically homozygous for the atypical plasma cholinesterase gene and 1 patient homozygous for the silent gene."( Dose-response relationship for mivacurium in patients with phenotypically abnormal plasma cholinesterase activity.
Jensen, FS; Ostergaard, D; Skovgaard, LT; Viby-Mogensen, J, 1995
)
0.78
" Using the slope for the log-dose/logit dose-response relationship of mivacurium (5."( Re-establishment of paralysis using mivacurium following apparent full recovery from mivacurium-induced neuromuscular block.
Justo, MD; Kopman, AF; Mallhi, MU; Neuman, GG, 1996
)
0.8
"The purpose of this study was to determine the dose-response relationships for edrophonium antagonism of mivacurium-induced neuromuscular block."( [Effects of different doses of edrophonium antagonism of mivacurium-induced neuromuscular block in the presence of nitrous oxide, propofol, and alfentanil anesthesia].
Drolet, P; Girard, M; Perreault, L; Ripart, J, 1996
)
0.75
"The purpose of this study was to determine the dose-response relationships for edrophonium antagonism of mivacurium-induced neuromuscular block."( Dose-response relationships for edrophonium antagonism of mivacurium-induced neuromuscular block during N2O-enflurane-alfentanil anaesthesia.
Drolet, P; Girard, M; Marcotte, J; Perreault, L, 1995
)
0.75
" Therefore mivacurium dosage should be reduced in patients with compromised renal function, mainly if there are additional systemic, especially hepatic diseases."( [Neuromuscular and cardiovascular effect of mivacurium in anesthesia induction in patients with renal failure].
Blobner, M; Jelen-Esselborn, S; Kling, M; Kochs, E; Mann, R; Schneck, HJ; Schneider, G, 1996
)
0.95
"We have compared the dose-response relationships of suxamethonium, mivacurium and atracurium and examined the interactions of suxamethonium with mivacurium or atracurium in humans by isobolographic analysis."( Interactions between suxamethonium and mivacurium or atracurium.
Chon, SU; Kim, KS; Na, DJ, 1996
)
0.8
"We have compared the dose-response relationships of mivacurium, pancuronium and their combination, and examined the interactions by isobolographic and fractional analyses."( Interactions between mivacurium and pancuronium.
Kim, DW; Kim, S; Shim, JC, 1997
)
0.87
"We compared the dose-response relationship and the neuromuscular blocking effects of mivacurium during infusions of esmolol in 40 anaesthetised rabbits."( Neuromuscular interactions between mivacurium and esmolol in rabbits.
Kim, KH; Kim, KS; Shin, WJ; Yoo, HK, 1998
)
0.8
"To evaluate the dose-response and maintenance requirements of a combination of mivacurium and pancuronium (cMP) in clinical practice."( Potency and hourly maintenance requirement of combinations of mivacurium and pancuronium in adults.
Erkola, O; Meretoja, OA; Rautoma, P, 1998
)
0.77
" Thirty patients received mivacurium and 20 patients received pancuronium to establish dose-response curves for these agents."( Potency and hourly maintenance requirement of combinations of mivacurium and pancuronium in adults.
Erkola, O; Meretoja, OA; Rautoma, P, 1998
)
0.84
"We compared the dose-response relationships of cisatracurium, mivacurium, atracurium, vecuronium and rocuronium and examined the interactions of cisatracurium with mivacurium, atracurium, vecuronium and rocuronium in humans by isobolographic and fractional analyses."( Neuromuscular interaction between cisatracurium and mivacurium, atracurium, vecuronium or rocuronium administered in combination.
Chon, SU; Chun, YS; Kim, KS; Suh, JK, 1998
)
0.79
"We compared the dose-response relationships and the neuromuscular blocking effects of mivacurium and rocuronium after chronic isepamicin therapy for 7 days in 56 anesthetized rabbits."( Rabbits treated with chronic isepamicin are resistant to mivacurium and rocuronium.
Chung, CW; Jun, JH; Kim, KS; Lee, KH; Shim, JC, 1999
)
0.77
"We studied the dose-response relationships and the neuromuscular blocking effects of mivacurium and rocuronium during chronic isepamicin therapy in rabbits."( Rabbits treated with chronic isepamicin are resistant to mivacurium and rocuronium.
Chung, CW; Jun, JH; Kim, KS; Lee, KH; Shim, JC, 1999
)
0.77
"kg-1 and construction of dose-response curves (n = 72)."( Potency and time course of mivacurium block during sevoflurane, isoflurane and intravenous anesthesia.
Carroll, MT; Hughes, DA; Lowry, DW; McCarthy, GJ; Mirakhur, RK; O'Hare, RA, 1999
)
0.6
"A normal mivacurium dosage (0."( Neuromuscular effects of mivacurium in 2- to 12-yr-old children with burn injury.
Chang, Y; Goudsouzian, NG; Martyn, JA; Patel, SS; Schwartz, AE; Szyfelbein, SK, 2000
)
1.03
"Forty adults undergoing elective surgery were randomly allocated in five dosing groups of mivacurium (50, 100, 150, 200, and 250 microg/kg)."( Differential sensitivity of abdominal muscles and the diaphragm to mivacurium: an electromyographic study.
Dhonneur, G; Kirov, K; Motamed, C, 2001
)
0.77
"The dose-response regression line of abdominal muscles differed from that of the diaphragm."( Differential sensitivity of abdominal muscles and the diaphragm to mivacurium: an electromyographic study.
Dhonneur, G; Kirov, K; Motamed, C, 2001
)
0.55
" Drug combinations containing equipotent concentrations of two agents were tested and dose-response curves were determined."( Isobolographic analysis of non-depolarising muscle relaxant interactions at their receptor site.
Dipp, NC; Fokt, RM; Kindler, CH; Paul, M; Yost, CS, 2002
)
0.31
"Sixty-four patients were included in a dose-response study, in which 32 young adults and 32 elderly patients received one of four doses of mivacurium."( Pharmacokinetics and pharmacodynamics of mivacurium in young adult and elderly patients.
Holm, H; Pedersen, NA; Skovgaard, LT; Viby-Mogensen, J; ØStergaard, D, 2002
)
0.78
"Dosage guidelines for muscle relaxants are based on dose-response studies, normally performed after several minutes of stable nitrous oxide (N O)-opioid anesthesia."( Duration of anesthesia before muscle relaxant injection influences level of paralysis.
Debaene, B; Donati, F; Plaud, B, 2002
)
0.31
" We compared the dose-response relationships and the neuromuscular blocking effects of mivacurium and rocuronium in 56 anesthetized rabbits immobilized in a plaster cast for 2, 4, and 6 wk."( The duration of immobilization causes the changing pharmacodynamics of mivacurium and rocuronium in rabbits.
Cho, SY; Jeon, JW; Kim, KS; Koh, MS; Shim, JH; Suh, JK, 2003
)
0.77
" Plasma cholinesterase activity was measured before and 3 and 30 min after pancuronium dosing in the pancuronium-mivacurium group and was measured before and after administration of saline in the mivacurium group."( Potentiation of mivacurium blockade by low dose of pancuronium: a pharmacokinetic study.
Bouleau, D; Combes, X; Duvaldestin, P; Farinotti, R; Feiss, P; Kirov, K; Menad, R; Motamed, C, 2003
)
0.88
"Thirty-two patients were included in a dose-response study, in which the patients received one of four doses of mivacurium."( Pharmacokinetics and pharmacodynamics of mivacurium in patients phenotypically heterozygous for the usual and atypical plasma cholinesterase variants (UA).
Gätke, MR; Pedersen, NA; Rasmussen, SN; Skovgaard, LT; Viby-Mogensen, J; Østergaard, D, 2003
)
0.8
"Short-acting agents for neuromuscular block (NMB) require frequent dosing adjustments for individual patient's needs."( Model-based control of neuromuscular block using mivacurium: design and clinical verification.
Leibundgut, D; Pfister, CA; Schumacher, PM; Stadler, KS; Wirz, R; Zbinden, AM, 2006
)
0.59
" We measured the onset time (time from administration of the muscle relaxant to 95% twitch depression), duration of block (times from dosing to 5% recovery after the first twitch [T1] of a TOF stimulus and to a TOF ratio of 80%), and the recovery indices (time between 25% and 75% recovery after T1 and between recovery of TOF ratios of 25% and 80%)."( [Clinical effect of mivacurium in morbidly obese patients].
Asensio, I; Barrio, J; García, V; Gramuntell, F; Molina, I; San Miguel, G, 2006
)
0.66
" Higher succinylcholine dosage is followed by lower incidence of myalgia."( Which muscle relaxants should be used in day surgery and when.
Bettelli, G, 2006
)
0.33
"Severe hepatitis was associated with a rightward shift of the mivacurium dose-response curves, but mild hepatitis had no effect."( The pharmacodynamics of mivacurium in the rabbit with carbon tetrachloride-induced liver disease.
Cheong, MA; Kim, KS; Lee, GS, 2007
)
0.89
"The dose-response and the time course of neuromuscular blockade of mivacurium differ in mild hepatitis compared with severe hepatitis, but required no adjustments of different doses for repeated injection after the desired depth of neuromuscular block, and had a negative correlation with the activity of plasma cholinesterase in both hepatic injuries."( The pharmacodynamics of mivacurium in the rabbit with carbon tetrachloride-induced liver disease.
Cheong, MA; Kim, KS; Lee, GS, 2007
)
0.88
" The dose-response curve was determined for both groups; potency was calculated using log-probit analysis."( Total intravenous anesthesia with propofol augments the potency of mivacurium.
Bracco, D; Cousineau, J; Decarie, P; Hemmerling, TM; Le, N, 2008
)
0.58
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
isoquinolinesA class of organic heteropolycyclic compound consisting of isoquinoline and its substitution derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (27)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1409747Half life in human2018ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3
Data Sets Representative of the Structures and Experimental Properties of FDA-Approved Drugs.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (594)

TimeframeStudies, This Drug (%)All Drugs %
pre-199018 (3.03)18.7374
1990's352 (59.26)18.2507
2000's171 (28.79)29.6817
2010's42 (7.07)24.3611
2020's11 (1.85)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 48.94

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index48.94 (24.57)
Research Supply Index6.75 (2.92)
Research Growth Index5.93 (4.65)
Search Engine Demand Index79.51 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (48.94)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials232 (37.54%)5.53%
Reviews57 (9.22%)6.00%
Case Studies93 (15.05%)4.05%
Observational0 (0.00%)0.25%
Other236 (38.19%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (9)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Pharmacodynamics of Mivacurium in Males and Females: A Study in Human Volunteers [NCT01906528]Phase 120 participants (Actual)Interventional2013-03-31Completed
A Prospective, Multi-center, Randomized Controlled Study of Neuromuscular Blocking Effect and Safety of Mivacurium Chloride in Pediatric Patients [NCT02117401]Phase 41,152 participants (Actual)Interventional2012-01-31Completed
[NCT01966484]100 participants (Anticipated)Interventional2013-10-31Completed
Evaluation of Effectiveness of Two Different Doses of Mivacurium in Modified Rapid Sequence Intubation for Emergency Surgery ,Prospective Randomized Double Blind Study [NCT06072534]100 participants (Anticipated)Interventional2023-09-01Recruiting
The Influence of Two Different Premedication Protocols for Endotracheal Intubation in Neonates on Cerebral Oxygenation [NCT01427985]Phase 424 participants (Actual)Interventional2011-06-30Completed
Use of Neuromuscular Blocking Agents and Neuromuscular Monitoring in 7 Danish Teaching Hospitals - a Cross-sectional Study [NCT02914119]30,430 participants (Actual)Observational [Patient Registry]2016-10-01Completed
Effect of Deep BLock on Intraoperative Surgical Conditions, Perioperative Hemodynamic Status and Respiratory Parameters Following Reversal With Sugammadex in Patients Undergoing Laparoscopic Renal and Prostate Surgery. [NCT01631149]Phase 424 participants (Actual)Interventional2012-06-30Completed
To Observe Mivacurium Chloramine Muscle Relaxation Effect in the Operation Anesthesia Patients With Liver Cirrhosis [NCT02473601]Phase 280 participants (Anticipated)Interventional2014-10-31Recruiting
An Observational Study of Mivacurium 0.2 mg/kg, Comparing Onset Time, Duration of Action and Effect on Intubating Conditions in Young (18 - 40 Years) and Elderly (= 80 Years) Patients [NCT05558137]70 participants (Actual)Observational2022-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01631149 (5) [back to overview]Breathing
NCT01631149 (5) [back to overview]Nausea and Vomiting
NCT01631149 (5) [back to overview]Post-operative Pain
NCT01631149 (5) [back to overview]Postoperative Sedation Score
NCT01631149 (5) [back to overview]Surgical Rating Scale
NCT02914119 (2) [back to overview]Last Recorded Train-of-four (TOF) Ratio Before Tracheal Extubation or Removal of Supraglottic Airway Device in Patients Receiving a Non-depolarizing NMBA
NCT02914119 (2) [back to overview]Time in Minutes From Tracheal Extubation or Removal of Supraglottic Airway Device to Discharge From Post-anaesthesia Care Unit in Cases Involving a Non-depolarizing NMBA With and Without Neuromuscular Monitoring, Respectively

Breathing

"In the recovery room the respiratory rate will be measured continuously using the Respir8 respiratory rate monitor. The data will be recorded on the CRF at 15 min intervals.~Breathing rate units are number of breaths as measured in 1 min.~Comparison by t-test: NS between treatments" (NCT01631149)
Timeframe: Measurements will be made during the stay in the recovery room for an average period of 3 hours

Interventionbreaths per min (Mean)
Moderate/Normal Surgical Block14.5
Deep Surgical Block14.5

[back to top]

Nausea and Vomiting

"Using a yes - no questionnaire, the patients will be asked whether they are nauseated or not or whether they vomited. In fact yes indicates the nr of participants.~No statistical analysis was performed." (NCT01631149)
Timeframe: Measurements will be made during the stay in the operating room for an average period of 3 hours

Interventionparticipants (Number)
Moderate/Normal Surgical Block0
Deep Surgical Block0

[back to top]

Post-operative Pain

"Using a 10 cm visual analogue score pain relief score will be measured. 0 = no pain 10 = most severe pain~No statistical analysis was performed!" (NCT01631149)
Timeframe: measurements are made in the recovery room following surgery for an average prior of 1 hour

Interventionunits on a scale (0-10 cm) (Mean)
Moderate/Normal Surgical Block2.6
Deep Surgical Block2.1

[back to top]

Postoperative Sedation Score

"Using a 5-point sedation scale, sedation levels will be obtained throughout the postoperative period.~0 = wide awake 5= severely sedated, The sedation data were averaged over time." (NCT01631149)
Timeframe: Measurements will be made during the stay in the operating room for an average period of 3 hours

Interventionunits on a scale (0-5) (Mean)
Moderate/Normal Surgical Block2.0
Deep Surgical Block1.3

[back to top]

Surgical Rating Scale

"During the procedure, the surgical condition will be scored by the surgeon using a 5-point surgical rating scale. In order to reduce variability in the surgical rating all surgeries will be performed by one single surgeon. The rating scale will be a 5-point ordinal scale ranging from 1 = poor condition to 5 = optimal surgical conditions. The surgeon will score the condition at 15 minute intervals. In case of a sudden change in surgical conditions additional scores will be added to the case record form. If conditions are poor (score 1 or 2), muscle relaxation will be increased, a score of 1 will be used.~In each subject the scores over time were averaged and a comparison between treatments was performed using a t-test" (NCT01631149)
Timeframe: Measurements will be made during the stay in the operating room for an average period of 3 hours

Interventionunits on a scale (1-5) (Mean)
Moderate/Normal Surgical Block4
Deep Surgical Block4.7

[back to top]

Last Recorded Train-of-four (TOF) Ratio Before Tracheal Extubation or Removal of Supraglottic Airway Device in Patients Receiving a Non-depolarizing NMBA

The train-of-four (TOF) ratio is the ratio between the last and first measurements after four stimuli of the ulnar nerve at 2 Hz. The ratio should be at least 0.9 before tracheal extubation. (NCT02914119)
Timeframe: in the period from induction of anaesthesia to termination of anaesthesia, usually 2 hours

InterventionTrain-of-four ratio (Median)
Eligible Patients0.97

[back to top]

Time in Minutes From Tracheal Extubation or Removal of Supraglottic Airway Device to Discharge From Post-anaesthesia Care Unit in Cases Involving a Non-depolarizing NMBA With and Without Neuromuscular Monitoring, Respectively

(NCT02914119)
Timeframe: in the period from induction of anaesthesia to discharge from the post-anaesthesia care unit, usually 180 minutes

InterventionMinutes (Median)
Eligible Patients97

[back to top]